The three-year award from the National Institute for Health and Care Research will support finalization of the test as well as initial validation studies.

The test is the last of three multiplex bloodstream infection panels that the firm has designed for its Liaison Plex molecular testing instrument.

Last week, readers were most interested in a story about the FDA's decision not to appeal a court decision vacating the agency's LDT rule.